학술논문

Risk of Non-infectious Uveitis with Metformin Therapy in a Large Healthcare Claims Database.
Document Type
Journal Article
Source
Ocular Immunology & Inflammation. Aug2022, Vol. 30 Issue 6, p1334-1340. 7p.
Subject
*METFORMIN
*UVEITIS
*ORAL medication
*IRIDOCYCLITIS
*INSURANCE claims
*ODDS ratio
*RETROSPECTIVE studies
*MEDICAL care
*CASE-control method
Language
ISSN
0927-3948
Abstract
Purpose: To determine if metformin is associated with noninfectious uveitis (NIU).Methods: Patients in an insurance claims database who initiated metformin (n = 359,139) or other oral anti-diabetic medications (n = 162,847) were followed for NIU development. Both cohort and case-control analyses were performed to assess differing exposure lengths using Cox and conditional logistic regression, respectively.Results: The hazard ratio (HR) for incident NIU was not significantly different between the metformin and non-metformin cohorts [HR = 1.19, 95% Confidence Interval (CI): 0.92-1.54, P = .19]. The case control analysis similarly showed no association between any metformin use 2 years before the outcome date and NIU [odds ratio (OR) = 0.64, 95% CI: 0.39-1.04, P = .07]. However, there was a protective 20 association between cumulative metformin duration [(445-729 days) adjusted OR (aOR) = 0.49, 95% CI: 0.27-0.90, P = .02] and dosage (>390,000 mg aOR = 0.44, 95% CI: 0.25-0.78, P = .001) compared with no metformin use.Conclusions: Our results suggest metformin use for longer durations may be protective of NIU onset. [ABSTRACT FROM AUTHOR]